Low-cost generation of clinical-grade layperson-friendly pharmacogenetic passports using oligonucleotide arrays

Pauline Lanting, Robert Warmerdam, Jelle Slager, Harm Brugge, Taichi Ochi, Marloes Benjamins, Esteban A. Lopera, Soesma Jankipersadsing, Jody Gelderloos, Daphne Teuben, Dennis Hendriksen, Bart Charbon, Lennart Johansson, Thijs H. Oude Munnink, Nienke De Boer-Veger, Lifelines NEXT, Lifelines Cohort Study, Bob Wilffert, Morris Swertz, Daan J. Touw, Patrick Deelen, Nine V.A.M. Knoers, Jackie A.M. Dekens, Lude Franke
{"title":"Low-cost generation of clinical-grade layperson-friendly pharmacogenetic passports using oligonucleotide arrays","authors":"Pauline Lanting, Robert Warmerdam, Jelle Slager, Harm Brugge, Taichi Ochi, Marloes Benjamins, Esteban A. Lopera, Soesma Jankipersadsing, Jody Gelderloos, Daphne Teuben, Dennis Hendriksen, Bart Charbon, Lennart Johansson, Thijs H. Oude Munnink, Nienke De Boer-Veger, Lifelines NEXT, Lifelines Cohort Study, Bob Wilffert, Morris Swertz, Daan J. Touw, Patrick Deelen, Nine V.A.M. Knoers, Jackie A.M. Dekens, Lude Franke","doi":"10.1101/2024.08.28.24312707","DOIUrl":null,"url":null,"abstract":"Pharmacogenomic (PGx) information is essential for precision medicine, enabling drug prescriptions to be personalized according to an individual's genetic background. Almost all individuals will carry a genetic marker that affects their drug response, so the ideal drug prescription for these individuals will differ from the population-level guidelines. Currently, PGx information is often not available at first prescription, reducing its effectiveness. Pharmacogenetic information is most often obtained using special assays, making it expensive and time-consuming to generate. We therefore hypothesized that we could also use genome-wide oligonucleotide genotyping arrays to generate comprehensive PGx information (PGx passports), thereby decreasing the cost and time required for PGx testing, and lowering the barrier to generating PGx information prior to first prescription. Taking advantage of existing genetic data generated in two biobanks, we developed and validated Asterix, a low-cost clinical-grade PGx passport pipeline for 12 PGx genes. In these biobanks we performed and clinically validated genetic variant calling and statistical phasing and imputation. In addition, we developed and validated a novel CYP2D6 copy number variant calling tool, foregoing the need to use separate PCR-based copy number detection. Ultimately, we returned 1227 PGx passports to biobank participants via a layperson-friendly app, improving knowledge of PGx among citizens. Our study demonstrates the feasibility of a low-cost clinical-grade PGx passport pipeline that could be readily implemented in clinical settings to enhance personalized healthcare, ensuring that patients receive the most effective and safe drug therapy based on their unique genetic makeup.","PeriodicalId":501447,"journal":{"name":"medRxiv - Pharmacology and Therapeutics","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"medRxiv - Pharmacology and Therapeutics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1101/2024.08.28.24312707","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Pharmacogenomic (PGx) information is essential for precision medicine, enabling drug prescriptions to be personalized according to an individual's genetic background. Almost all individuals will carry a genetic marker that affects their drug response, so the ideal drug prescription for these individuals will differ from the population-level guidelines. Currently, PGx information is often not available at first prescription, reducing its effectiveness. Pharmacogenetic information is most often obtained using special assays, making it expensive and time-consuming to generate. We therefore hypothesized that we could also use genome-wide oligonucleotide genotyping arrays to generate comprehensive PGx information (PGx passports), thereby decreasing the cost and time required for PGx testing, and lowering the barrier to generating PGx information prior to first prescription. Taking advantage of existing genetic data generated in two biobanks, we developed and validated Asterix, a low-cost clinical-grade PGx passport pipeline for 12 PGx genes. In these biobanks we performed and clinically validated genetic variant calling and statistical phasing and imputation. In addition, we developed and validated a novel CYP2D6 copy number variant calling tool, foregoing the need to use separate PCR-based copy number detection. Ultimately, we returned 1227 PGx passports to biobank participants via a layperson-friendly app, improving knowledge of PGx among citizens. Our study demonstrates the feasibility of a low-cost clinical-grade PGx passport pipeline that could be readily implemented in clinical settings to enhance personalized healthcare, ensuring that patients receive the most effective and safe drug therapy based on their unique genetic makeup.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
利用寡核苷酸阵列低成本生成临床级非专业人员易懂的药物基因护照
药物基因组学(PGx)信息对精准医疗至关重要,它能根据个人的遗传背景开出个性化处方。几乎所有个体都会携带影响其药物反应的遗传标记,因此针对这些个体的理想药物处方将不同于人群指南。目前,PGx 信息往往无法在首次处方时获得,从而降低了其有效性。药物基因信息通常需要通过特殊检测才能获得,因此成本高昂且耗时。因此,我们假设也可以使用全基因组寡核苷酸基因分型阵列来生成全面的 PGx 信息(PGx 通行证),从而降低 PGx 检测所需的成本和时间,降低在首次处方前生成 PGx 信息的门槛。利用在两个生物库中生成的现有基因数据,我们开发并验证了 Asterix,这是一种针对 12 个 PGx 基因的低成本临床级 PGx 通行证管道。在这些生物库中,我们进行了基因变异调用、统计分期和归因,并进行了临床验证。此外,我们还开发并验证了一种新型的 CYP2D6 拷贝数变异调用工具,从而避免了单独使用基于 PCR 的拷贝数检测。最终,我们通过一个非专业人士也能使用的应用程序向生物库参与者返还了 1227 份 PGx 护照,提高了公民对 PGx 的认识。我们的研究证明了低成本临床级 PGx 护照流水线的可行性,该流水线可在临床环境中随时使用,以加强个性化医疗,确保患者根据其独特的基因构成接受最有效、最安全的药物治疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Tucaresol: An Oral Candidate Drug With Two Distinct Antiviral Mechanisms. Comparative Risk of the Onset of Atrial Fibrillation after Icosapent Ethyl versus Omega-3–Acid-Ethyl-Esters Adjuvant to Statins A Novel Maxillofacial Technology for Drug Administration-A Randomized Controlled Trial Using Metronidazole. Protective Effects of Psychiatric Medications against COVID-19 Mortality Before Vaccines Anti-cancer effect of memantine as adjunctive therapy in metastatic colon cancer: A pilot randomized controlled clinical trial
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1